Pneumococcal polysaccharide vaccination of healthcare workers during an influenza pandemic is cost-effective from a societal perspective but not from a hospital perspective without external subsidy.
Mark S. Roberts, MD, MPP
Advertisement
Articles by Mark S. Roberts, MD, MPP
Advertisement
Latest Updated Articles
- Cost-Effectiveness of Pneumococcal Polysaccharide Vaccine Among Healthcare Workers During an Influenza Pandemic
Published: March 9th 2010 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
3
Pulling Back Funding for Research Could Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
4
Flow Cytometry Tool Could Improve Treatment Monitoring in MS
5
